Yasodha Natkunam, M.D., Ph.D

Publication Details

  • CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma BLOOD Bhatt, S., Ashlock, B. M., Natkunam, Y., Sujoy, V., Chapman, J. R., Ramos, J. C., Mesri, E. A., Lossos, I. S. 2013; 122 (7): 1233-1242


    Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a protease-cleavable linker to a microtubule-disrupting agent monomethyl auristatin E (MMAE). Brentuximab vedotin is an effective treatment for relapsed CD30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas. Herein, we demonstrated that PEL cell lines and primary tumors express CD30 and thus may serve as potential targets for brentuximab vedotin therapy. In vitro treatment with brentuximab vedotin decreased cell proliferation, induced cell cycle arrest and triggered apoptosis of PEL cell lines. Furthermore, in vivo brentuximab vedotin promoted tumor regression and prolonged survival of mice bearing previously reported UM-PEL-1 tumors as well as UM-PEL-3 tumors derived from a newly established and characterized KSHV and EBV positive PEL cell line. Overall, our results demonstrate for the first time that brentuximab vedotin may serve as an effective therapy for PEL and provide strong preclinical indications for evaluation of brentuximab vedotin in clinical studies of PEL patients.

    View details for DOI 10.1182/blood-2013-01-481713

    View details for Web of Science ID 000323392900023

    View details for PubMedID 23838350

Stanford Medicine Resources:

Footer Links: